About the Editors

Editor-in-Chief

Alan D. T. Barrett, PhD
Director, Sealy Center for Vaccine Development
University of Texas Medical Branch, Galveston, Texas, USA

Doctor Alan Barrett serves as Director, Sealy Center for Vaccine Development and Director of the World Health Organization Collaborating Center for Vaccine Research, Evaluation and Training for Emerging Infectious Diseases. He is a Professor in the Departments of Pathology and Microbiology & Immunology at University of Texas, Medical Branch (UTMB). Dr. Barrett is a leading expert in the fields of vaccine development for flavivirus and bunyavirus. Dr. Barrett has been focusing his research mainly on the pathogenesis and potential counter measures of West Nile and dengue viruses, and is funded by a number of grants from the NIH. Dr. Barrett obtained his Ph.D. in Virology from the University of Warwick, Coventry, U.K.

Associate Editors

Paul A. MacAry, PhD
Director, LSI Immunology Programme & Co-Chair CREATE-HUJ Consortium
National University of Singapore, Singapore

Associate Professor Paul MacAry received his BSc (Hons) in Molecular Genetics from Glasgow University in 1993 and his PhD in Immunology from GKT, University of London in 1998.  He performed post-doctoral researches in the Cambridge University Institute for Medical Research (CIMR) and since 2005 has been an independent investigator in the Department of Microbiology and Immunology program at the National University of Singapore (NUS). The multi-disciplinary research in his laboratory covers the entire spectrum of scientific endeavour, from basic research to industrial applications with an emphasis on antibody biology, immune repertoire mapping and protein engineering applications in infectious diseases. Professor MacAry was a founding member and Meetings Secretary for the Singaporean Society of Immunology (SSI) - Singapore’s first international learned society - and the founding scientist for two biotechnology companies, BSCR LTD founded in Cambridge in 2004 and Antibody Cradle LTD founded in Singapore in 2012.

Veronika von Messling, Dr. med. vet.
Director of the Veterinary Medicine
Paul-Ehrlich-Institut, Langen, Germany

Prof. Dr. Veronika von Messling is Director of the Veterinary Medicine Division at the Paul-Ehrlich Institute, the German Federal Institute of Vaccines and Biomedicines, in Langen, Germany.  She obtained her veterinary degree and her doctorate degree in veterinary virology from the Veterinary School Hannover, Germany.  After postdoctoral training at Mayo Clinic in Rochester, MN, she was Assistant Professor at INRS-Institut Armand-Frappier in Laval, QC, and then Associate Professor at Duke-NUS Medical School, Singapore. Her research interest lies in characterizing the pathogenesis of respiratory viruses to develop novel prophylactic and therapeutic strategies.  

Pei-Yong Shi, PhD
I.H. Kempner Professor of Human Genetics, Department of Biochemistry and Molecular Biology
University of Texas Medical Branch, Galveston, Texas, USA

Pei-Yong Shi studies flavivirus replication and develops antiviral and vaccine. He received his Ph.D. in virology in 1996 from Georgia State University. After postdoctoral training at Yale University, he joined Bristol-Myers Squibb as a Principal Scientist to develop HIV and HCV therapeutics from 1998 to 2000. He then moved to the Wadsworth Center, New York State Department of Health, to study West Nile virus. From 2008 to 2015, he served as Executive Director to lead drug discovery at Novartis Institute for Tropical Diseases. He recently joined University of Texas Medical Branch. His group developed the first infectious clone of the epidemic strain of West Nile virus, discovered two cap methylation activities of flavivirus NS5 protein, identified essential RNA elements for flavivirus replication, established various platforms for flavivirus vaccine and drug discovery, and pioneered therapeutics development for dengue virus.

David H. Walker, MD, Professor
Department of Pathology
University of Texas Medical Branch, Galveston, Texas, USA

David Walker is the Director of the Center for Biodefense and Emerging Infectious Diseases, and Professor and former Chairman of the Department of Pathology at the University of Texas Medical Branch at Galveston. Dr. Walker’s research has elucidated mechanisms of immunity to Rickettsia and Ehrlichia, developed animal models for investigating rickettsioses and ehrlichioses, and contributed to elucidating the pathology and pathophysiology of Lassa fever, Rocky Mountain spotted fever, Mediterranean spotted fever, and human monocytotropic ehrlichiosis. Among emerging infections, he contributed to the discovery, characterization, and/or epidemiology of Anaplasma phagocytophilum (human granulocytotropic anaplasmosis), Rickettsia japonica (Japanese spotted fever), R. felis (flea-borne spotted fever), and E. chaffeensis (human monocytotropic ehrlichiosis).